---
title: "Lakewood-Amedex Biotherapeutics sets 1-for-10 reverse split, trading June 22"
url: "https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-1-10-reverse-split-trading-june/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2026-06-17"
section: "Listings"
tickers: "NASDAQ:LABT"
source: "https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm"
summary: "Outstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT."
---

By the aibio.space news desk.

Sources

- [Lakewood-Amedex Biotherapeutics Inc. 8-K (2026-06-17)](https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm)

[LABT](https://aibio.space/companies/lakewood-amedex-biotherapeutics/)

2026-06-17

# Lakewood-Amedex Biotherapeutics sets 1-for-10 reverse split, trading June 22, 2026

Tickers [LABT](https://aibio.space/companies/lakewood-amedex-biotherapeutics/)

Outstanding shares will fall from about 17,506,577 to about 1,750,789. The stock stays on the Nasdaq Capital Market as LABT.

## Key facts

- **Company**: Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT)

- **News type**: Listings

- **Primary source**: [Lakewood-Amedex Biotherapeutics Inc. 8-K (2026-06-17)](https://www.sec.gov/Archives/edgar/data/2079272/000121390026069512/ea0294845-8k_lakewood.htm)

*The facade of a neoclassical court building at dusk. Photo: Carol M Highsmith, CC0, via rawpixel. The picture shows the field, not the companies named.*

Lakewood-Amedex Biotherapeutics Inc. (Nasdaq: [LABT](https://aibio.space/companies/lakewood-amedex-biotherapeutics/)) said in an 8-K filed June 17, 2026 that it filed a Certificate of Change with the Nevada Secretary of State on June 15, 2026 to effect a 1-for-10 reverse stock split. The split covers its issued and outstanding and authorized shares of common stock. The board approved it unanimously on June 1, 2026.

The split becomes effective at 4:01 p.m. Eastern Time on June 19, 2026. The common stock will begin trading on a split-adjusted basis when Nasdaq opens on June 22, 2026. It will continue to trade on The Nasdaq Capital Market under the symbol LABT, with a new CUSIP number, 51255A201.

Every ten shares will be exchanged for one share, and fractional shares will be rounded up to the next higher whole share. Issued and outstanding shares will fall from approximately 17,506,577 to approximately 1,750,789. Authorized common stock will be reduced proportionately to 12,500,000 shares.

Equitable adjustments will be made to shares issuable on exercise or conversion of equity awards, preferred stock and warrants, and to the related conversion and exercise prices.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

LABT

Lakewood-Amedex Biotherapeutics Inc.

NASDAQ · United States

Open the starter desk

## More in Listings

Listings

### [Propanc Biopharma faces Nasdaq delisting on bid price, plans to appeal](https://aibio.space/news/propanc-biopharma-faces-nasdaq-delisting-bid-price-plans-appeal/)

Oct 29, 2026

Listings

### [Reviva asks stockholders to approve reverse split of up to 1-for-100](https://aibio.space/news/reviva-asks-stockholders-approve-reverse-split-up-1-100/)

Oct 29, 2026

Listings

### [Nasdaq to delist Glucotrack shares after bid price exception ends](https://aibio.space/news/nasdaq-delist-glucotrack-shares-after-bid-price-exception-ends/)

Oct 28, 2026

---
Source page: https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-1-10-reverse-split-trading-june/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Lakewood-Amedex Biotherapeutics sets 1-for-10 reverse split, trading June 22", 2026-06-17, https://aibio.space/news/lakewood-amedex-biotherapeutics-sets-1-10-reverse-split-trading-june/